BRAF and neoplasm: More importantly, dabrafenib (Dab), a v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor is a drug capable of slowing tumor growth, and its combination with miR-200c turned out to enhance cancer cells’ sensitivity to such medicine by inhibiting the expression of PD-L1 (Nguyen et al., 2021).